PPARG and liver dysplastic nodule: Our findings show that PIO, a PPAR-γ agonist, ameliorate DN and this is associated with downregulation of the NLRP3 inflammasome, potentially providing a new underlying mechanism responsible for the beneficial effect of PIO for DN.